PREVAIL Act

General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) H.R.9221 - RESTORE Patent Rights Act of 2024 S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S.4840 - RESTORE Patent Rights Act of 2024 -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $70,413 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies H.R. 9474 Patent Restoration Act (PERA) of 2024 S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patent reform legislation; H.R. 4370/S. 2220 - The PREVAIL Act (118th Congress).

Client expense: Not reported · Firm income: $120,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to legislation regarding patents; H.R. 4370/ S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (118th Congress); S. 2140 - Patent Eligibility Restoration Act (118th Congress); H.R. 9221/ S. 4840 - RESTORE Patent Rights Act of 2024 (118th Congress).

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) H.R.9221 - RESTORE Patent Rights Act of 2024 S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S.4840 - RESTORE Patent Rights Act of 2024 -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $75,967 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent quality issues and preserving the Patent Trial and Appeal Board (PTAB) - In the 118th Congress bills were S. 2220, HR 4370, the PREVAIL Act; S. 2140 the Patent Eligibility Restoration Act of 2023

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent quality issues and preserving the Patent Trial and Appeal Board (PTAB) - In the 118th Congress bills were S. 2220, HR 4370, the PREVAIL Act; S. 2140 the Patent Eligibility Restoration Act of 2023

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patent quality, Inter Partes Review, and the Patent Trial and Appeal Board (PTAB). Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370 (in the 118th Congress); Patent Eligibility Restoration Act, S. 2140 and HR 9474 (in the 118th Congress); RESTORE Patent Rights Act of 2024, S. 4840 and HR 9221 (in the 118th Congress).

Client expense: Not reported · Firm income: Not reported

U.S House Consideration of the Defending Education Transparency and Ending Rogue Regimes Engaging in Support for federal policies that would enhance university tech transfer capabilities. NIST Framework on the exercise of march-in rights and how this could impact university tech transfer. Research Security provisions considered as part of FY2025 National Defense Authorization Act. H.R. 1398, Protect Americas Innovation and Economic Security from CCP Act H.R. 1516, DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act Support for Mid Atlantic Semiconductor Hub Proposal to Department of Commerce S. 2220/H.R. 4370, Support for PREVAIL Act & Opposition to WH and NIST Proposed Framework on March-In Rights (Expanding Based on Price)

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent reform H.R. 4370 and S. 2220, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act

Client expense: $580,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patent Eligibility Restoration Act. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.4878: The Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.8134: Restoring Americas Leadership In Innovation Act of 2024. H.R.9221/S.4840: Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024.

Client expense: $530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent abuse issues. S. 150 Affordable Prescriptions for Patients Act of 2023. S. 79 Interagency Patent Coordination Act. S. 2780 Medication Affordability and Patent Integrity Act S. 142 Preserve Access to Affordable Generics and Biosimilars Act Joint USPTO-FDA Collaboration Initiatives. S. 2140/H.R.9474 Patent Eligibility Restoration Act of 2023 S. 2220/H.R.4370 PREVAIL Act S. 3583 A bill to address patent thickets. H.R. 6986 To address patent thickets. S.5573 A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2220 / H.R. 4370, PREVAIL Act S.2140, Patent Eligibility Restoration Act Issues related to copyright and AI H.R. 10550, The Preventing Abuse of Digital Replicas Act (PADRA) S. 4875, NO FAKES Act of 2024

Client expense: $917,059 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office

Discussions regarding Right to Repair efforts (H.R. 906 - Right to Equitable and Professional Auto Industry Repair Act) (entire bill); General discussions on patent reform legislation: PREVAIL Act (S. 2220, H.R. 4370) and Patent Eligibility Restoration Act of 2023 (S.2140) - entire bills; Discussions regarding automotive right to repair efforts (H.R. 906 - Right to Equitable and Professional Auto Industry Repair Act; entire bill); (H.R.8070 - Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; Sec. 857) (S.4638 - National Defense Authorization Act for Fiscal Year 2025; Sec. 828).

Client expense: $1,760,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2140: Patent Eligibility Restoration Act of 2023: Provisions regarding Section 2(b )(1 )(B)(i) and Section 2(b )(1 )(B)(ii), which exclude most inventions implemented in software from patent eligibility as these inventions are not patent ineligible in other countries. S. 2220/H.R. 4370: Promoting and Respecting Economically Vital American Innovation Leadership Act of 2023 (PREVAIL ACT): Seeking an amendment to balance incentives within the Patent Trial and Appeal Board (PTAB).

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 and S. 2220 (PREVAIL Act), regarding administrative updates to the U.S. Patent and Trademark Office S. 2140 (Patent Eligibility Restoration Act of 2023), regarding administrative updates to the U.S. Patent and Trademark Office

Client expense: Not reported · Firm income: $60,000

Government targets: SENATE

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6986: To address patent thickets. - Provisions related to patents S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act S. 3583: A bill to address patent thickets. - Provisions related to patents S. 4878: REMEDY Act S. 5573: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Request for Information Regarding the Draft Interagency Guidance Framework for considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues AI patent policy issues

Client expense: $920,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 . S. 1250 Drug-price Transparency for Consumers Act S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve Access to Affordable Generics and Biosimilars Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting S.2140 Patent Eligibility Restoration Act of 2023 S.2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress. H.R. 3535 Advancing Americas Interests Act H.R. 5475 Prohibiting Adversarial Patents Act of 2023 S.3385/HR 8333-- BIOSECURE Act BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities Issues related to FDA/PTO coordination S.2780 Medication Affordability and Patent Integrity Act Issues related to skinny labeling S. 3583/HR 6986 To Address Patent Thickets S. 1956 Invent It Here, Make It Here Act S 5573 Skinny Labels, Big Savings Act

Client expense: $2,780,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2410, Patent Eligibility Restoration Act S. 2220 & HR 4370, PREVAIL Act S. 2934, SHOP SAFE Act/HR. 8684, SHOP SAFE Act H.R. 9221 and S 4840: RESTORE Act Patents in general

Client expense: $520,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent reform H.R. 4370 and S. 2220, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act

Client expense: $590,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 and S. 2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act A bill to amend title 35, United States Code, to invest in inventors in the United States, maintain the United States as the leading innovation economy in the world, and protect the property rights of the inventors that grow the economy of the United States, and for other purposes (ALL). H.R. 9474 and S. 2140: Patent Eligibility Restoration Act A bill to amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes (ALL). H.R. 9455 and S. 4713: Inventor Diversity for Economic Advancement (IDEA) Act A bill to amend chapter 11 of title 35, United States Code, to require the voluntary collection of demographic information for patent inventors, and for other purposes (ALL).

Client expense: $70,000 · Firm income: Not reported

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6986: To address patent thickets. - Provisions related to patents S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act S. 3583: A bill to address patent thickets. - Provisions related to patents S. 4878: REMEDY Act S. 5573: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Request for Information Regarding the Draft Interagency Guidance Framework for considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues AI patent policy issues

Client expense: $7,560,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to technology and information policy, including issues related to consumer and childrens privacy, data protection, intellectual property, artificial intelligence, educational technology, competition, and innovation; S.1409/H.R.7891, Kids Online Safety Act; H.R.7890, Children and Teens Online Privacy Protection Act; H.R.8818, American Privacy Rights Act of 2024; S.222/H.R.4370, PREVAIL Act; S.2140, Patent Eligibility Restoration Act; H.R.9197, Small Business Artificial Intelligence Advancement Act; H.R.9194, Nucleic Acid Screening for Biosecurity Act; H.R.9211, LIFT AI Act; H.R.9215, Workforce for AI Trust Act; H.R.9402, NSF AI Education Act of 2024; H.R.9403, Expanding AI Voices Act; H.R.5077, CREATE AI Act; H.R.9497, AI Advancement and Reliability Act; H.R.9466, AI Development Practices Act; H.R.7569, DEFIANCE Act of 2024; H.R.8989, TAKE IT DOWN Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Signed a letter of support Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220, H.R. 4370) and the Patent Eligibility Restoration (PERA) Act (S. 2140). Signed a comment letter provides comment on Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) regarding the recent initiative on standards development or the licensing of standard essential patients.

Client expense: Not reported · Firm income: Not reported

Government targets: Patent & Trademark Office (PTO)

H. R. 4370, S. 2220, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act), Issues pertaining to policy issues affecting higher education institutions. Issues pertaining to March-in rights.

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patent reform legislation; H.R.9474 - Patent Eligibility Restoration Act (PERA) of 2024; S. 2140 - Patent Eligibility Restoration (PERA) Act of 2023; H.R. 4370/S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act.

Client expense: Not reported · Firm income: $110,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act Opposition to FTC proposal to limit non-compete agreements ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies H.R. 9474 Patent Restoration Act (PERA) of 2024

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) ---Patent eligibility for inventions created using AI tools Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights ---NIST RFI Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March in Rights ---Reasonable Pricing Clause Compulsory Licensing Data Privacy Issues ---H.R.7085: BIOSECURE Act ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---S.3558: A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---H.R.8818: American Privacy Rights Act of 2024 ---Bio COMPETES (Draft) ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---House GOP RFI on Supply Chain Diversity in Patenting ---S.2566: Inventor Diversity for Economic Advancement (IDEA) Act Drug Patenting ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.113: Prescription Pricing for the People Act of 2023 ---S.142: Preserve Access to Affordable Generics and Biosimilars Act ---S.148: Stop STALLING Act ---S.150: Affordable Prescriptions for Patients Act of 2023 ---S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents. ---S.2780: Medication Affordability and Patient Integrity Act ---S.3583/H.R.6986: A bill to address patent thickets ---S.5573: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. ---H.R.5475: Prohibiting Adversarial Patents Act of 2023 (Fitzgerald - WI) ---H.R.6275: Protecting Consumer Access to Generic Drugs Act ---FTC Orange Book Delisting Initiative ---Orange Book Listing ---PTO Proposed Rules on Terminal Disclaimer Practice ---Restrictions on Intellectual Property Rights Foreign Drug Data Protection Law ---H.R.7085: BIOSECURE Act ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---Bio COMPETES (Draft) ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---House GOP RFI on Supply Chain Intellectual Property Enforcement ---China ---TRIPS Waiver Patent Reform ---H.R.4575: Prohibiting Adversarial Patents Act (PAPA) ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.2140: Patent Eligibility Restoration Act (PERA) ---S.2220/H.R.4370: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act ---Patent Litigation Reform ---The USPTO Request for Comments: Experimental Use Defense 89 Fed.Reg 53963 Patenting of Biological Inventions ---S.2140: Patent Eligibility Restoration Act (PERA) ---Section 101 Modernization World Health Organization (WHO) ---WHO Pandemic Preparedness Accord World Intellectual Property Office (WIPO) ---Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge World Trade Organization (WTO) ---TRIPS Waiver

Client expense: $1,460,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office

S. 2140, Patent Eligibility Restoration Act (PERA) of 2023 S. 2220/ HR 4370, PREVAIL Act Patent Protection and IP Reform issues, generally

Client expense: $310,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)

Issues related to patent reform legislation; H.R.4370/S.2220 - The PREVAIL Act.

Client expense: Not reported · Firm income: $170,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to legislation regarding patents; H.R. 4370/ S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act; S. 2140 - Patent Eligibility Restoration Act; H.R. 9221/ S. 4840 - RESTORE Patent Rights Act of 2024.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent abuse issues. S. 150/H.R. 9070 - Affordable Prescriptions for Patients Act of 2023. S. 79 - Interagency Patent Coordination Act. S. 2780 - Medication Affordability and Patent Integrity Act. S. 142 - Preserve Access to Affordable Generics and Biosimilars Act. Joint USPTO-FDA Collaboration Initiatives. H.R. 9474/S. 2140 - Patent Eligibility Restoration Act of 2023. H.R. 4370/S. 2220 - PREVAIL Act. S. 3583 - A bill to address patent thickets. H.R. 6986 - A bill to address patent thickets. H.R. 10545 - American Relief Act

Client expense: Not reported · Firm income: $80,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE

Issues relating to patent litigation and processes, protecting and modernizing intellectual property rights, and USPTO policies and operations: H.R. 4370/S.2220, "PREVAIL" Act (Senate and House); S.2140, Patent Eligibility Restoration Act of 2023; H.R. 3535, Advancing Americas Interests Act.

Client expense: $1,490,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to intellectual property legislation and regulation; S. 2140, Patent Eligibility Restoration Act; S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 9221/S. 4840, RESTORE Patent Rights Act of 2024

Client expense: Not reported · Firm income: $70,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

Intellectual property and patent issues; Standard Essential Patents; IP enforcement at the International Trade Commission; S. 2140, Patent Eligibility Restoration Act of 2023; H.R. 4370/S. 2220, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act)

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) H.R.9221 - RESTORE Patent Rights Act of 2024 S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S. 1241 - Domenic and Eds Law S.4840 - RESTORE Patent Rights Act of 2024 -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $41,265 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patent policy and reform, including to address patent thickets (HR 6986, S. 3583) and Promoting and Respecting Economically Vital American Innovation Leadership Act (S. 2220, HR 4370), and Patent Eligibility Restoration Act of 2023 (S. 2140) FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79) and Medication Affordability and Patent Integrity Act (S. 2780, HR 5429) Prescription Pricing for the People Act of 2023 (S.113); Preserve Access to Affordable Generics and Biosimilars Act (S.142); Affordable Prescriptions for Patients Act of 2023 (S.150).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patent law, including the Promoting and Respecting Economically Vital American Innovation Leadership (S. 2220 and HR 4370) and the Patent Eligibility Restoration Act (S. 2140).

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023 S. 4713 - The IDEA Act (Inventor Diversity for Economic Advancement Act) S. 4840/ H.R. 9221 - Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent quality issues - S. 2220, HR 4370, the PREVAIL Act; S. 2140 the Patent Eligibility Restoration Act of 2023

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor S.142 - Preserve Access to Affordable Generics and Biosimilars Act as it related to patent settlement issues. Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews. Monitor issues relating to the structure of the Patent Trial and Appeal Board. S.150 - Affordable Prescriptions for Patients Act of 2023. H.R.6986 - To address patent thickets. Court decisions on skinny labeling issue. Issues relating to the Patent Eligibility Restoration Act - S.2140. Issues relating to the PREVAIL Act - S.2220/H.R.4370.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patient Eligibility Restoration Act of 2023. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act of 2024. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.5573: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products.

Client expense: $800,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE